Europe Orthobiologics Market

Europe Orthobiologics Market Size (2022 to 2027)

The size of the orthobiologics market in Europe was worth USD 1.35 billion in 2022 and is estimated to be growing at a CAGR of 5.31%, to reach USD 1.75 billion by 2027.

Orthobiologics is referred to as Regenerative cellular therapies. The orthobiological products comprise growth factors that improve and stimulate pain relief, tissue healing, and normal function. The rise in sports injures, and traffic accidents are projected to drive the growth of the European orthobiologics market in the forecast period. In addition, the rise in the number of spinal diseases and disorders occurrences is expected to boost the orthobiologics market growth in Europe.

Europe is the second-largest market for orthobiologics, owing to the rising prevalence of osteoarthritis and osteoporosis. Furthermore, the market is growing faster due to technical advancements in European countries, and there is a burgeoning need for bone graft alternatives and other biologics that have a beneficial impact.

According to UK National Health Services, people aged 65 and up are at a higher risk of orthopedic disorders, one of the primary driving factors in the UK market’s contribution to the global market. However, in the forecasted 2022 - 2027, the European market’s growth will be hampered by high costs and poor transplant processes.

An increase in patient demand for minimally invasive procedures is likely to boost the market for orthobiologics. On the other side, the rising cost of orthobiologics based treatments is likely to limit the orthobiologics market growth over the forecast period. However, the high costs of orthopedic implants and an unfavorable regulatory environment is another significant factor expected to inhibit the market’s growth rate. Furthermore, the market is expected to face additional challenges due to a lack of medical experts, particularly in developing and underdeveloped economies, and stringent government regulations on product approvals.

Impact of COVID-19 on the European orthobiologics market:

Due to the COVID-19 pandemic, the orthobiologics market has suffered a fall in growth. The imposition of lockdown has disrupted the global supply chain. Due to the crisis scenario, all medical treatments were postponed or canceled, except for emergency patients. During the outbreak, telemedicine services were critical in delivering high-quality operations to patients.

This research report on the Europe Orthobiologics Market has been segmented & sub-segmented into the following categories:

By Product: 

• Viscosupplementation
• Demineralized Bone Matrices
• Synthetic Orthobiologics
• Bone Morphogenic Protein
• Allografts
• Plasma-Rich Protein
• Bone Marrow Aspirate Concentrate

By Application: 

• Osteoarthritis and Degenerative Arthritis
• Spinal Fusion
• Fracture Recovery
• Soft Tissue Injuries
• Maxillofacial & Dental Applications

By End Users: 

• Hospitals
• Orthopedic Clinics
• Ambulatory Care Centres
• Research and Academic Institutes
• Dental Clinics & Facilities

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Regionally, the European orthobiologics market had the second-largest market for orthobiologics in the world by share in 2020. Factors such as the growing incidence of musculoskeletal and orthopedic diseases and rising government support are expected to drive the market growth in the region.

KEY MARKET PLAYERS:

A few notable companies in the European orthobiologics market profiled in this report are Medtronic, DePuy Synthes, Zimmer Biomet, Bioventus, Stryker, Harvest Technologies, Globus, Orthofix International, RTI Surgical, K2M Group, Kuros Biosciences, among others.